Abstract Number: 221

Secukinumab shows sustained response in subjectswith moderate-to-severe plaque psoriasis: asubanalysis of the ERASURE phase 3 study

A. Wylie on behalf of M. Lebwohl , R. Vender , A. Menter , A. Karpov , C. Papavassilis

Meeting: 2015 Dermcoll

Session Information

Date: -

Session Title: Poster Presentations

Session Time: -

Introduction: Secukinumab, an anti–IL-17A antibody,
demonstrated PASI75 and a score of 0 or 1 on a modified,
5-point investigator’s global assessment (IGA-mod 2011
0/1) efficacies compared to placebo at Week 12 (ERASURE
study). Furthermore, long-term efficacy with an acceptable
safety profile at Week 52 was noted in subjects with
moderate-to-severe plaque psoriasis. This subanalysis
evaluates sustainability of response to secukinumab to
Week 52.

Methods: In this 52-week, double-blind, placebocontrolled
study, subjects aged ≥18 years were randomized
(1:1:1) to subcutaneous injection of secukinumab 300 mg
(n = 245), 150 mg (n = 245) (1x/wk for 4 weeks, then q4wk
starting at Week 4), or placebo (n = 248). This subanalysis
summarises statistics of PASI75 or IGA mod 2011 0/1 to
Week 52.

Results: At Week 12, PASI75 and IGA-mod 2011 0/1
responses were achieved, respectively, by 81.6% and 65.3%
(secukinumab 300 mg group), 71.6% and 51.2% (150 mg
group), and 4.5% and 2.4% (placebo group) (P < 0.0001 for each dose vs placebo). Response rates further improved to Week 16 with PASI75 and IGA-mod 2011 0/1 responders being, respectively, 86.1% and 73.5% (secukinumab 300 mg group) and 77.4% and 58.2% (150 mg group). At Week 52, PASI75 and IGA-mod 2011 0/1 responses were sustained, respectively, in 78.6% and 67.8% (secukinumab 300 mg group) and 65.7% and 51.4% (150 mg group). Secukinumab was well tolerated with no unexpected safety findings. Conclusions: This subanalysis indicates a sustained response to secukinumab in subjects with moderate-tosevere plaque psoriasis over 52 weeks, with 300 mg exhibiting greater sustainability than the 150 mg dose.